Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

NCT05651022 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, Adult
HCC - Hepatocellular Carcinoma
CRC (Colorectal Cancer)
Pancreatic Adenocarcinoma
NSCLC Non-small Cell Lung Cancer
Squamous Cell Cancer of the Head and Neck
UC (Urothelial Cancer)
MSI-H Cancer

Interventions

DRUG: Decoy20
DRUG: Tislelizumab

Sponsor

Indaptus Therapeutics, Inc

Collaborators

[object Object]